Top

20-11-2023 | Infliximab | Abdominal Radiology

CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn’s disease

Authors: Fulong Song, Mengtian Ma, Shumin Zeng, Fang Shao, Weiyan Huang, Zhichao Feng, Pengfei Rong

Abstract

Purpose

Accurately predicting the treatment response in patients with Crohn’s disease (CD) receiving infliximab therapy is crucial for clinical decision-making. We aimed to construct a prediction model incorporating radiomics and body composition features derived from computed tomography (CT) enterography for identifying individuals at high risk for infliximab treatment failure.

Methods

This retrospective study included 137 patients with CD between 2015 and 2021, who were divided into a training cohort and a validation cohort with a ratio of 7:3. Patients underwent CT enterography examinations within 1 month before infliximab initiation. Radiomic features of the intestinal segments involved were extracted, and body composition features were measured at the level of the L3 lumbar vertebra. A model that combined radiomics with body composition was constructed. The primary outcome was the occurrence of infliximab treatment failure within 1 year. The model performance was evaluated using discrimination, calibration, and decision curves.

Results

Fifty-two patients (38.0%) showed infliximab treatment failure. Eight significant radiomic features were used to develop the radiomics model. The model incorporating radiomics model score, skeletal muscle index (SMI), and creeping fat showed good discrimination for predicting infliximab treatment failure, with an area under the curve (AUC) of 0.88 (95% CI 0.81, 0.95) in the training cohort and 0.83 (95% CI 0.66, 1.00) in the validation cohort. The favorable clinical application was observed using decision curve analysis.

Conclusions

We constructed a comprehensive model incorporating radiomics and muscle volume, which could potentially be used to facilitate the individualized prediction of infliximab treatment response in patients with CD.

Available only for authorised users

Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn’s disease. Lancet 389(10080):1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1 CrossRefPubMed

Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ (2010) The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 105(2):289–297. https://doi.org/10.1038/ajg.2009.579 CrossRefPubMed

Leal RF, Planell N, Kajekar R, Lozano JJ, Ordas I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Panes J, Salas A (2015) Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFalpha therapy. Gut 64(2):233–242. https://doi.org/10.1136/gutjnl-2013-306518 CrossRefPubMed

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, Gonzalez-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G (2020) ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180 CrossRefPubMed

Cushing K, Higgins PDR (2021) Management of Crohn disease: a review. JAMA 325(1):69–80. https://doi.org/10.1001/jama.2020.18936 CrossRefPubMedPubMedCentral

Singh S, Fumery M, Sandborn WJ, Murad MH (2018) Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther 48(4):394–409. https://doi.org/10.1111/apt.14852 CrossRefPubMed

Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, Danese S, Vermeire S, Teillaud JL, Lemann M, Chowers Y (2010) Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 4(4):355–366. https://doi.org/10.1016/j.crohns.2010.04.004 CrossRefPubMed

Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, Sandborn WJ, Investigators PRS (2010) Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 105(7):1574–1582. https://doi.org/10.1038/ajg.2010.78 CrossRefPubMed

Gisbert JP, Panes J (2009) Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104(3):760–767. https://doi.org/10.1038/ajg.2008.88 CrossRefPubMed

10.

Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S (2021) A novel model based on serum biomarkers to predict primary non-response to infliximab in Crohn’s disease. Front Immunol 12:646673. https://doi.org/10.3389/fimmu.2021.646673 CrossRefPubMedPubMedCentral

11.

Zapater P, Almenara S, Gutierrez A, Sempere L, Garcia M, Laveda R, Martinez A, Scharl M, Cameo JI, Linares R, Gonzalez-Navajas JM, Wiest R, Rogler G, Frances R (2019) Actual anti-TNF trough levels relate to serum IL-10 in drug-responding patients with Crohn’s disease. Inflamm Bowel Dis 25(8):1357–1366. https://doi.org/10.1093/ibd/izz012 CrossRefPubMed

12.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T, Group UKIBDPS (2019) Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 4(5):341–353. https://doi.org/10.1016/S2468-1253(19)30012-3 CrossRefPubMed

13.

Gisbert JP, Chaparro M (2020) Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 14(5):694–709. https://doi.org/10.1093/ecco-jcc/jjz195 CrossRefPubMed

14.

Bruining DH, Zimmermann EM, Loftus EV Jr, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused P (2018) Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn’s disease. Radiology 286(3):776–799. https://doi.org/10.1148/radiol.2018171737 CrossRefPubMed

15.

Ognibene NM, Basile M, Di Maurizio M, Petrillo G, De Filippi C (2016) Features and perspectives of MR enterography for pediatric Crohn disease assessment. Radiol Med 121(5):362–377. https://doi.org/10.1007/s11547-015-0613-2 CrossRefPubMed

16.

Cicero G, Alibrandi A, Blandino A, Ascenti V, Fries W, Viola A, Mazziotti S (2023) DWI ratios: New indexes for Crohn’s disease activity at magnetic resonance enterography? Radiol Med (Torino) 128(1):16–26. https://doi.org/10.1007/s11547-022-01573-7 CrossRefPubMed

17.

Napolitano M, Munari AM, Di Leo G, Panarisi NAR, Zuin G, Fava G, Vecchi M, Sardanelli F, Zuccotti GV (2021) MR enterography grading of pediatric ileocolonic Crohn disease activity based on a single bowel segment. Radiol Med (Torino) 126(11):1396–1406. https://doi.org/10.1007/s11547-021-01409-w CrossRefPubMed

18.

Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T (2022) Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut 71(12):2587–2597. https://doi.org/10.1136/gutjnl-2021-326562 CrossRefPubMed

19.

Baker ME, Hara AK, Platt JF, Maglinte DD, Fletcher JG (2015) CT enterography for Crohn’s disease: optimal technique and imaging issues. Abdom Imaging 40(5):938–952. https://doi.org/10.1007/s00261-015-0357-4 CrossRefPubMed

20.

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, Zegers CML, Gillies R, Boellard R, Dekker A, Aerts HJWL (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441–446. https://doi.org/10.1016/j.ejca.2011.11.036 CrossRefPubMedPubMedCentral

21.

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures. They Are Data Radiology 278(2):563–577. https://doi.org/10.1148/radiol.2015151169 CrossRefPubMed

22.

Zhu C, Hu J, Wang X, Li C, Gao Y, Li J, Ge Y, Wu X (2022) A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab. Eur Radiol 32(10):6628–6636. https://doi.org/10.1007/s00330-022-08989-9 CrossRefPubMed

23.

Li X, Liang D, Meng J, Zhou J, Chen Z, Huang S, Lu B, Qiu Y, Baker ME, Ye Z, Cao Q, Wang M, Yuan C, Chen Z, Feng S, Zhang Y, Iacucci M, Ghosh S, Rieder F, Sun C, Chen M, Li Z, Mao R, Huang B, Feng ST (2021) Development and validation of a novel computed-tomography enterography radiomic approach for characterization of intestinal fibrosis in Crohn’s disease. Gastroenterology 160(7):2303–2316. https://doi.org/10.1053/j.gastro.2021.02.027 CrossRefPubMed

24.

Cruz-Jentoft AJ, Sayer AA (2019) Sarcopenia. Lancet 393(10191):2636–2646. https://doi.org/10.1016/S0140-6736(19)31138-9 CrossRefPubMed

25.

Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D (2019) Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 25(1):67–73. https://doi.org/10.1093/ibd/izy212 CrossRefPubMed

26.

Grillot J, D’Engremont C, Parmentier AL, Lakkis Z, Piton G, Cazaux D, Gay C, De Billy M, Koch S, Borot S, Vuitton L (2020) Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn’s disease. Clin Nutr 39(10):3024–3030. https://doi.org/10.1016/j.clnu.2020.01.001 CrossRefPubMed

27.

Adams DW, Gurwara S, Silver HJ, Horst SN, Beaulieu DB, Schwartz DA, Seidner DL (2017) Sarcopenia is common in overweight patients with inflammatory bowel disease and may predict need for surgery. Inflamm Bowel Dis 23(7):1182–1186. https://doi.org/10.1097/MIB.0000000000001128 CrossRefPubMed

28.

Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT (2017) Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. Eur J Clin Nutr 71(6):773–777. https://doi.org/10.1038/ejcn.2017.10 CrossRefPubMed

29.

Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, Gonzalez-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustins E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J, European CS, Colitis O, Abdominal R (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164. https://doi.org/10.1093/ecco-jcc/jjy113 CrossRefPubMed

30.

Campbell JP, Teigen L, Manski S, Blumhof B, Guglielmo FF, Shivashankar R, Shmidt E (2022) Sarcopenia is more prevalent among inflammatory bowel disease patients undergoing surgery and predicts progression to surgery among medically treated patients. Inflamm Bowel Dis 28(12):1844–1850. https://doi.org/10.1093/ibd/izac013 CrossRefPubMed

31.

Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N (2018) Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 67(3):914–923. https://doi.org/10.1002/hep.29578 CrossRefPubMed

32.

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33(5):997–1006. https://doi.org/10.1139/H08-075 CrossRefPubMed

33.

Yueying C, Jing F, Qi F, Jun S (2023) Infliximab response associates with radiologic findings in bio-naive Crohn’s disease. Eur Radiol. https://doi.org/10.1007/s00330-023-09542-y CrossRefPubMedPubMedCentral

34.

Zhu C, Wang X, Wang S, Hu J, Gao Y, Li C, Li J, Wu X (2023) Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients. Heliyon 9(4):e14594. https://doi.org/10.1016/j.heliyon.2023.e14594 CrossRefPubMedPubMedCentral

35.

Ordas I, Rimola J, Alfaro I, Rodriguez S, Castro-Poceiro J, Ramirez-Morros A, Gallego M, Giner A, Barastegui R, Fernandez-Clotet A, Masamunt M, Ricart E, Panes J (2019) Development and validation of a simplified magnetic resonance index of activity for Crohn’s disease. Gastroenterology 157(2):432–439. https://doi.org/10.1053/j.gastro.2019.03.051 CrossRefPubMed

36.

Lafeuille P, Hordonneau C, Vignette J, Blayac L, Dapoigny M, Reymond M, Rouquette O, Sollelis E, Boube M, Magnin B, Pereira B, Buisson A (2021) Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease. Aliment Pharmacol Ther 53(5):577–586. https://doi.org/10.1111/apt.16232 CrossRefPubMed

37.

Minordi LM, Larosa L, Barbaro B, Angelino A, Broglia D, Cipri C, Scaldaferri F, Manfredi R, Natale L (2023) How the radiologist must reason for a correct diagnosis in patients with small bowel mural thickening studied by CT or MRI: a pictorial review. Curr Probl Diagn Radiol 52(5):393–411. https://doi.org/10.1067/j.cpradiol.2023.03.006 CrossRefPubMed

38.

Vilela EG (2012) Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol. https://doi.org/10.3748/wjg.v18.i9.872 CrossRefPubMedPubMedCentral

39.

Guglielmo FF, Anupindi SA, Fletcher JG, Al-Hawary MM, Dillman JR, Grand DJ, Bruining DH, Chatterji M, Darge K, Fidler JL, Gandhi NS, Gee MS, Grajo JR, Huang C, Jaffe TA, Park SH, Rimola J, Soto JA, Taouli B, Taylor SA, Baker ME (2020) Small bowel crohn disease at CT and MR enterography: imaging atlas and glossary of terms. Radiographics 40(2):354–375. https://doi.org/10.1148/rg.2020190091 CrossRefPubMed

40.

Bettenworth D, Bokemeyer A, Baker M, Mao R, Parker CE, Nguyen T, Ma C, Panés J, Rimola J, Fletcher JG, Jairath V, Feagan BG, Rieder F (2019) Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut 68(6):1115–1126. https://doi.org/10.1136/gutjnl-2018-318081 CrossRefPubMed

41.

Chirra P, Sharma A, Bera K, Cohn HM, Kurowski JA, Amann K, Rivero MJ, Madabhushi A, Lu C, Paspulati R, Stein SL, Katz JA, Viswanath SE, Dave M (2022) Integrating radiomics with clinicoradiological scoring can predict high-risk patients who need surgery in Crohn’s disease: a pilot study. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izac211 CrossRefPubMedCentral

42.

Li XH, Feng ST, Cao QH, Coffey JC, Baker ME, Huang L, Fang ZN, Qiu Y, Lu BL, Chen ZH, Li Y, Bettenworth D, Iacucci M, Sun CH, Ghosh S, Rieder F, Chen MH, Li ZP, Mao R (2021) Degree of creeping fat assessed by computed tomography enterography is associated with intestinal fibrotic stricture in patients with Crohn’s disease: a potentially novel mesenteric creeping fat index. J Crohns Colitis 15(7):1161–1173. https://doi.org/10.1093/ecco-jcc/jjab005 CrossRefPubMedPubMedCentral

43.

Ha CWY, Martin A, Sepich-Poore GD, Shi B, Wang Y, Gouin K, Humphrey G, Sanders K, Ratnayake Y, Chan KSL, Hendrick G, Caldera JR, Arias C, Moskowitz JE, Ho Sui SJ, Yang S, Underhill D, Brady MJ, Knott S, Kaihara K, Steinbaugh MJ, Li H, McGovern DPB, Knight R, Fleshner P, Devkota S (2020) Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans. Cell 183(3):666–683. https://doi.org/10.1016/j.cell.2020.09.009 CrossRefPubMedPubMedCentral

44.

Chang JT (2020) Pathophysiology of inflammatory bowel diseases. N Engl J Med 383(27):2652–2664. https://doi.org/10.1056/NEJMra2002697 CrossRefPubMed

45.

Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S (2020) Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 52(9):1453–1468. https://doi.org/10.1111/apt.16096 CrossRefPubMed

Title: CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn’s disease
Authors: Fulong Song
Mengtian Ma
Shumin Zeng
Fang Shao
Weiyan Huang
Zhichao Feng
Pengfei Rong
Publication date: 20-11-2023
Publisher: Springer Milan
Keywords: Infliximab
Crohn's Disease
Computed Tomography
Computed Tomography
Published in: La radiologia medica
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-023-01748-w

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn’s disease

Abstract

Purpose

Methods

Results

Conclusions

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content